Incident Comorbidity Among Patients with Rheumatoid Arthritis Treated or Not with Low-dose Glucocorticoids: A Retrospective Study
Authors:
- Maurizio MazzantiniMMMaurizio Mazzantini
- Rosaria TalaricoRTRosaria Talarico
- Marica DoveriMDMarica Doveri
- Arianna ConsensiACArianna Consensi
- Massimiliano CazzatoMCMassimiliano Cazzato
- Laura BazzichiLBLaura Bazzichi
- Stefano BombardieriSBStefano Bombardieri
Open Access
- 15 September 2010
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 37 (11) , 2232-2236
Abstract
Objective. To assess the prevalence of comorbidity in a cohort of patients with rheumatoid arthritis (RA), treated or not with low-dose glucocorticoids (GC) and who have been followed for at least 10 years. Methods. This was a retrospective study by review of medical records. Results. We identified 365 patients: 297 (81.3%) were GC users (4–6 mg methylprednisolone daily) and 68 (18.7%) were nonusers. We found that fragility fractures occurred in 18.2% of GC users and in 6.0% of GC nonusers (p < 0.02); arterial hypertension in 32.3% of GC users and in 10.4% of GC nonusers (p < 0.0005); acute myocardial infarction in 13.1% of GC users and in 1.5% of the nonusers (p < 0.01). Prevalence of diabetes mellitus, cataract, and infections was comparable. We divided GC users into groups of different duration of GC therapy: < 2, 2–5, and > 5 years; the mean duration of GC treatment was 1.3 ± 0.5, 3.6 ± 1.1, and 12.1 ± 5.1 years, respectively. GC treatment for > 5 years was associated with significantly higher prevalence of fragility fractures (26.6%; p < 0.001 vs the other groups), arterial hypertension (36.7%; p < 0.0002 vs nonusers and GC users < 2 years), myocardial infarction (16.1%; p < 0.01 vs nonusers), and infections (9.7%; p < 0.005 vs the other groups). GC treatment for 2–5 years was associated with a significantly higher prevalence of arterial hypertension (30.0%; p < 0.01) compared to nonusers. Conclusion. Patients with RA treated with low-dose GC compared to patients never treated with GC show a higher prevalence of fractures, arterial hypertension, myocardial infarction, and serious infections, especially after 5 years of GC treatment. The high prevalence of myocardial infarction and fractures in patients with RA suggests that a more accurate identification of risk factors and prevention measures should be adopted when longterm GC treatment is needed.Keywords
This publication has 13 references indexed in Scilit:
- Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysisRheumatology, 2009
- Use of oral corticosteroids and the risk of acute myocardial infarctionAtherosclerosis, 2007
- Effects of glucocorticoids on radiological progression in rheumatoid arthritisCochrane Database of Systematic Reviews, 2007
- Very low‐dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2005
- A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2005
- Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular DiseaseAnnals of Internal Medicine, 2004
- Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trialAnnals of the Rheumatic Diseases, 2004
- Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialAnnals of Internal Medicine, 2002
- Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study GroupRheumatology, 1998
- The Effect of Glucocorticoids on Joint Destruction in Rheumatoid ArthritisNew England Journal of Medicine, 1995